HCC827 Metastatic Tumor Model Service for Lung Cancer

The HCC827 metastatic tumor model for lung cancer is a clinically relevant in vivo system that recapitulates the dissemination of EGFR-mutant non-small cell lung cancer (NSCLC), enabling the evaluation of candidate therapies against tumor spread before they advance further in development. Alfa Cytology delivers end-to-end construction, longitudinal monitoring, and multidimensional endpoint analysis of HCC827 metastatic models, giving oncology programs a robust preclinical platform to interrogate anti-metastatic efficacy, targeted therapy response, and resistance mechanisms with dependable, publication-quality data.

Overview of HCC827 Metastatic Tumor Model for Lung Cancer

HCC827 is a human NSCLC cell line of adenocarcinoma origin, established from a 39-year-old Caucasian female patient. Its defining molecular feature is an activating deletion in exon 19 of the epidermal growth factor receptor (EGFR) gene (E746-A750), accompanied by markedly elevated EGFR copy number. This genotype renders the cells exquisitely sensitive to EGFR tyrosine kinase inhibitors (TKIs) such as gefitinib, erlotinib, afatinib, and osimertinib, while acquired resistance in this background is frequently linked to MET amplification or secondary pathway activation. The line also shows high PD-L1 expression, adding immunotherapy relevance to its research value.

Fig 1. HCC827ER xenograft efficacy in the erlotinib-resistant NSCLC model: 5×10⁶ HCC827/ER cells subcutaneously implanted into nude mice (~75 mm³ randomization) treated with vehicle, HJD (50 mg/kg), erlotinib (20 mg/kg), or combination for 27 days — gross tumor photographs and mean tumor volume curves show dramatic regression in the combination group, with caspase-3/Ki67/STAT3/Bcl-2 immunohistochemistry confirming the mechanism. (Zhou, Xiaowen, et al., 2021)

Beyond conventional subcutaneous xenografts, the HCC827 metastatic tumor model exploits the line's aggressive, EGFR-addicted phenotype to study lung cancer dissemination in in vivo settings. HCC827 cells are introduced into immunodeficient mice via metastasis-prone routes—most commonly tail vein injection, with intracardiac, orthotopic lung, or splenic delivery as alternatives—so that cells colonize the lung and other distant organs in a manner that mirrors hematogenous metastasis. Tumor burden can be tracked longitudinally by bioluminescence imaging when luciferase-labeled cells are used, and at endpoint, metastatic nodules are quantified and confirmed by histopathology (H&E staining), immunohistochemistry, and molecular analyses. This model is widely applied to benchmark anti-metastatic agents, study TKI resistance in vivo, and evaluate combination strategies in an EGFR-mutant context that reflects a major NSCLC patient subgroup.

Cell Line Information: HCC827

HCC827 is one of the best-characterized EGFR-mutant NSCLC models in oncology research. The table below summarizes the key attributes of this cell line.

Our Services

Drawing on extensive experience with EGFR-mutant lung cancer models, Alfa Cytology offers flexible, study-ready HCC827 metastatic tumor model services covering every stage of a preclinical program—from cell line authentication and route selection to inoculation, imaging-based monitoring, dosing, and comprehensive endpoint analysis. Whether the goal is to test a novel targeted agent, model acquired TKI resistance, or quantify anti-metastatic activity, our team tailors each study design to your compound's mechanism and decision-making needs.

Workflow of HCC827 Metastatic Tumor Model Construction

Construction of the HCC827 metastatic tumor model follows a standardized, quality-controlled pipeline. The workflow below outlines how the model is built and evaluated from cell preparation through final data delivery.

1. Cell line authentication and preparation: HCC827 cells are verified by STR profiling and confirmed mycoplasma-free, then expanded under optimized culture conditions to ensure consistent viability and tumorigenicity at inoculation.
2. Route and readout selection: Based on the scientific objective, the metastasis route is selected—tail vein for lung colonization, intracardiac for widespread dissemination, or orthotopic lung implantation for organ-specific growth. Cells are stably labeled with luciferase or fluorescent reporters when longitudinal imaging is required.
3. Mouse model setup: Immunodeficient mice (e.g., NOD/SCID or athymic nude mice) are acclimated and randomized, with all procedures performed under approved animal ethics protocols.
4. Tumor cell inoculation: HCC827 cells (typically on the order of 1×10⁶ cells per mouse, resuspended in PBS or serum-free medium) are administered through the chosen route under sterile conditions.
5. Metastasis monitoring: Metastatic burden is tracked over time by in vivo bioluminescence or fluorescence imaging; body weight and general health status are recorded throughout the study.
6. Treatment initiation: Once metastatic signals are established, animals are randomized into treatment groups and dosed according to the study design, with vehicle controls included for reference.
7. Endpoint analysis: At the study endpoint, mice are euthanized and organs (with the lung as the primary target) are excised; metastatic nodules are counted, tumor tissues are processed for H&E histopathology, immunohistochemistry, and molecular or biomarker analyses as required.
8. Data compilation and reporting: All imaging, tumor burden, and histology data are analyzed statistically and assembled into a clear, comprehensive study report supporting downstream decision-making.

Fig 2. HCC827 Metastatic Tumor Model construction workflow.

Case Study-HCC827 Metastatic Tumor Model Development

Alfa Cytology has successfully developed HCC827 metastatic tumor models in support of preclinical oncology programs targeting EGFR-driven lung cancer. In these studies, the model has been applied to evaluate the anti-metastatic potential of candidate compounds, to benchmark responses against standard-of-care EGFR inhibitors, and to explore resistance-related questions under controlled in vivo conditions. Detailed case data and study designs are available upon request, and our team can adapt model parameters—such as inoculation route, dosing schedule, and endpoint assays—to fit the specific requirements of each client program.

Why Choose Alfa Cytology?

Partnering with Alfa Cytology means working with a CRO that combines deep model expertise with responsive, study-focused support. Key reasons clients select our HCC827 metastatic tumor model service include:

• Extensive hands-on experience with EGFR-mutant NSCLC models, including HCC827 and its resistant derivatives.
• Multiple metastasis induction routes and imaging options to match diverse study objectives.
• Rigorous cell line authentication and quality control at every project milestone.
• Customizable dosing regimens, endpoints, and biomarker analyses tailored to your compound.
• Longitudinal in vivo imaging capabilities for real-time, non-invasive metastasis tracking.
• Transparent communication and timely delivery of comprehensive, decision-ready reports.

Contact Us

If you are planning a preclinical program around EGFR-mutant lung cancer, our team is ready to help you design the right HCC827 metastatic tumor model study. Contact us today to discuss your project requirements, timelines, and study design options. Reach out now and let Alfa Cytology accelerate your oncology drug discovery with reliable, high-quality metastatic model data.

For research use only. Not intended for any clinical use.